Opioid Withdrawal Symptom Mitigation Data Can Support A Labeling Claim

While symptom reduction is a clinically meaningful benefit that can support an indication, data on withdrawal treatment completion can provide confirmatory evidence of a drug's effect, US FDA advisory committee members say in their review of US WorldMeds' lofexidine.